ClinicalTrials.gg
Not yet recruitingNCT07939087Updated Nov 16, 2026

A Study to Evaluate the Pharmacokinetics and Safety Between HIP2604 and RLD2606 in Healthy Volunteers

A Phase 1 interventional study of RLD2606 and HIP2604 1 in Healty Volunteers, sponsored by Hanmi Pharmaceutical Company Limited. Not yet recruiting at 1 site in South Korea. Open to participants aged 19 Years to 64 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Hanmi Pharmaceutical Company Limited · Phase 1, Interventional, and Treatment

Updated Nov 16, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
19 Years to 64 Years
Sex
All
01

Study summary

The purpose of this study is to evaluate the pharmacokinetics and safety compared to HIP2604 and RLD2606 in healthy volunteers.

02

Conditions studied

  • Healty Volunteers
03

In context

Lead sponsor

Hanmi Pharmaceutical Company Limited is the lead sponsor of 191 studies on the registry; 12 are open to participants now.

Of its 11 completed or terminated interventional studies of FDA-regulated products, 6 (55%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 19\~64 years in healthy volunteers
  • 18 kg/m\^2 ≤ ≤ 30 kg/m\^2, weight(men) ≥50kg / weight(women) ≥45kg
  • Subjects who voluntarily decides to participate in this clinical trial and agree in writing to ensure compliance with the clinical trial
  • Agrees that the person, spouse, or partner uses appropriate medically recognized and does not provide sperm or eggs from the date of administration of the first drug to 7 days after the administration of the last investigational drug

Exclusion criteria

Exclusion Criteria:

  • Subjects who have received any product by participating in a bioequivalence study or any other clinical study within 6 months prior to study initiation (first dose)
  • Subjects who judged ineligible by the investigator
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
36 participants (estimated)

Study arms

  • Experimental
    Arm A

    Drug: RLD2606 · Drug: HIP2604 1 · Drug: HIP2604 2

  • Experimental
    Arm B

    Drug: RLD2606 · Drug: HIP2604 1 · Drug: HIP2604 2

  • Experimental
    Arm C

    Drug: RLD2606 · Drug: HIP2604 1 · Drug: HIP2604 2

  • Experimental
    Arm D

    Drug: RLD2606 · Drug: HIP2604 1 · Drug: HIP2604 2

  • Experimental
    Arm E

    Drug: RLD2606 · Drug: HIP2604 1 · Drug: HIP2604 2

  • Experimental
    Arm F

    Drug: RLD2606 · Drug: HIP2604 1 · Drug: HIP2604 2

Interventions

  • DrugRLD2606

    Take 1 tablet once per period

  • DrugHIP2604 1

    Take 1 tablet once per period

  • DrugHIP2604 2

    Take 1 tablet once per period

06

What researchers measure

Primary outcomes

  1. AUCt

    Time frame: 0~36hr

  2. Cmax

    Time frame: 0~36hr

Secondary outcomes

  1. AUCinf

    Time frame: 0~36hr

  2. AUCt/AUCinf

    Time frame: 0~36hr

  3. t1/2

    Time frame: 0~36hr

  4. Tmax

    Time frame: 0~36hr

  5. CL/F

    Time frame: 0~36hr

  6. Vz/F

    Time frame: 0~36hr

  7. Ka

    Time frame: 0~36hr

07

Study locations

1 site
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jan 2027; primary completion for Feb 2027, 0 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 10, 2026
First posted
Nov 16, 2026
StartEst.
Jan 12, 2027
Primary completionEst.
Feb 5, 2027
CompletionEst.
Feb 5, 2027
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07939087
Responsible party
Sponsor
First posted
Nov 16, 2026
Start date
Jan 12, 2027 (estimated)
Primary completion
Feb 5, 2027 (estimated)
Completion
Feb 5, 2027 (estimated)
Last update
Nov 16, 2026

Study contacts

Jee Won Shon
Contact
jeewon.shon@hanmi.co.kr
82-2-410-9037

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion